Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Revenue (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Revenue for 14 consecutive years, with $18.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue rose 9.76% year-over-year to $18.6 million, compared with a TTM value of $67.0 million through Dec 2025, up 0.58%, and an annual FY2025 reading of $65.3 million, down 3.42% over the prior year.
  • Revenue was $18.6 million for Q4 2025 at Enanta Pharmaceuticals, up from $15.1 million in the prior quarter.
  • Across five years, Revenue topped out at $27.6 million in Q4 2021 and bottomed at $14.6 million in Q3 2024.
  • Average Revenue over 5 years is $19.1 million, with a median of $18.7 million recorded in 2022.
  • Peak annual rise in Revenue hit 15.93% in 2021, while the deepest fall reached 27.11% in 2021.
  • Year by year, Revenue stood at $27.6 million in 2021, then fell by 14.7% to $23.6 million in 2022, then dropped by 23.67% to $18.0 million in 2023, then fell by 5.8% to $17.0 million in 2024, then rose by 9.76% to $18.6 million in 2025.
  • Business Quant data shows Revenue for ENTA at $18.6 million in Q4 2025, $15.1 million in Q3 2025, and $18.3 million in Q2 2025.